A preclinical study has recently demonstrated that although PSMA-targeted PET in a specific murine model of glioblastoma is feasible and resulted in high TBR, absolute tumoral uptake values remained low limiting the applicability of this murine model for PSMA-targeted therapy [34]. The gene discussed is FOLH1; the disease is glioblastoma.